Merck & Co., Inc. (MRK) — closed signal from September 6, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 5, 2025.
Predicted vs. what happened
What happened
Reached its target in 73 days.
The thesis — published September 6, 2025
Merck looks ready for a careful rebound after a sharp pullback. Strong late-stage results for its drug enlicitide and a $6B bond to help fund the Verona deal strengthen its future lineup. Market mood is fairly positive, and signs suggest the recent slide may be easing. If that holds, the price could work back toward earlier highs over the next three months, as long as buying interest remains steady.
Primary drivers
- Late-stage trial for enlicitide succeeded, lifting future treatment hopes
- Company raised $6B in bonds to help pay for the Verona purchase
- Recent slide looks overdone, with signs the downturn may be ending
- Strong trading activity suggests more buyers are stepping in than usual
How it played out
MRK: target reached in 73 days
Lyra published MRK at $83.17 on September 6, 2025, with a short-term thesis for 15% growth. The thesis pointed to late-stage enlicitide results, a $6B bond raise tied to the Verona purchase, a pullback that looked overdone, and stronger trading activity.
Inside the window, the stock reached the $93.91 target in 73 days. It kept rising to a $104.94 peak on November 25, with a 26.2% peak gain. It ended the window at $98.87, still above the target. The thesis played out.
What happened during the window
On October 30, 2025, Merck reported third-quarter results and raised its 2025 profit guidance. Barron's also reported that Keytruda and Winrevair sales missed estimates that day.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.